The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report.
J Aerosol Med Pulm Drug Deliv
; 34(4): 262-264, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1276115
ABSTRACT
Despite the various parenchymal presentation of coronavirus disease 2019 (COVID-19) pneumonia, the involvement of the vascular component, the reduction of perfusion in noninjured part of the lung and secondary right to left shunt play an important role in the genesis of the respiratory insufficiency. We present the case of a 72-year-old woman admitted to Livorno Hospital for severe respiratory insufficiency due to SARS-CoV-2 infection unresponsive to noninvasive in whom administration of nebulized phosphodiesterase 3 (PDE3) inhibitor enoximone was able to improve oxygenation avoiding tracheal intubation. Intravenous infusions of phosphodiesterase inhibitors are commonly used as pulmonary vasodilators in the management of pulmonary hypertension. This is the first case showing that inhaled route administration of PDE3 inhibitor enoximone could be important in the management of COVID-19 hypoxemia, to restore perfusion in noninjured part of the lung, improving oxygenation and avoiding risks of systemic infusion.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Circulation
/
Enoximone
/
Phosphodiesterase 3 Inhibitors
/
COVID-19 Drug Treatment
/
Lung
/
Hypoxia
Type of study:
Case report
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
Language:
English
Journal:
J Aerosol Med Pulm Drug Deliv
Journal subject:
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
Jamp.2021.0024
Similar
MEDLINE
...
LILACS
LIS